HOOK (HOOKIPA Pharma, Inc.) Market Value to Book Value Ratio

Official company branding of hookipapharma.com (HOOK)

The investment potential of HOOKIPA Pharma Inc. (HOOK) depends on the results of medical trials and deals with industry behemoths. The ratio of market capitalization to book value demonstrates asset value dynamics, where 0.32 is recorded as the baseline value. Capital stability is supported by advances from immunotherapy partners, although the lack of sales is leading to a gradual depletion of cash reserves.

HOOK hookipapharma.com: Market Value to Book Value in the range 07/04/2022 - 08/24/2025
Original product of hookipapharma.com

A comparative asset analysis allows investors to determine the extent of a business's market overvaluation. This metric compares the current share price with net assets on the balance sheet, revealing the premium for future growth. Stable demand for medical innovations at HOOKIPA Pharma Inc. (HOOK) minimizes macroeconomic dependence, supporting the cost of capital. This factor stabilizes the fundamental valuation. The price action of these figures on the market-to-book capitalization chart reflects the current level of investment risk.

Main competitors

ARGX: Market Value to Book Value Ratio|BNTX (biontech.de) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GOSS|Market Value to Book Value Ratio KalVista Pharmaceuticals KALV|Capitalization to Book Value Ratio septerna.com (SEPN)|PVLA: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Savara Inc SVRA|Market Capitalization to Book Value Ratio Rigel Pharmaceuticals Inc (RIGL)|ANAB: Market Value to Book Value|Market Value to Book Value Ratio ATXS|ENGN (engene.com) - Market-to-Book Ratio|Market Value to Book Value Ratio RAPT (RAPT Therapeutics)|Market-to-Book Ratio JBIO|Market Value to Book Value Ratio ACRS|Market Capitalization to Book Value Ratio Kyverna Therapeutics, Inc (KYTX)|Market Capitalization to Book Value Ratio TLSA|cabalettabio.com - Market Capitalization to Book Value|Market Value to Book Value Ratio Ventyx Biosciences, Inc.|THTX - Market Capitalization to Net Assets|AVTX: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Eledon Pharmaceuticals, Inc|AGEN - Market Cap to Net Assets Ratio|Market Value to Book Value CLYM|ZURA - Market Value to Book Value Ratio|Market Capitalization to Net Assets aTyr Pharma Inc (ATYR)|Market Capitalization to Book Value Ratio Adagene Inc.|Market Value to Book Value ImageneBio IMA|Shattuck Therapeutics - Market Capitalization to Book Value Ratio|EQ: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio connectbiopharm.com CNTB|IMUX (Immunic) - Market Value to Book Value|Market Value to Book Value Ratio ATRA|Market Cap to Net Assets Ratio InflaRx GmbH|Market Capitalization to Book Value Ratio XFOR|Market Capitalization to Book Value Ratio adicetbio.com ACET|Market Cap to Net Assets Ratio Celularity|Market Value to Book Value INmune Bio Inc INMB|Market Capitalization to Book Value Ratio BRNS (Barinthus Bio)|KZR: Market Capitalization to Book Value|Market Value to Book Value Ratio SAB Biotherapeutics|akaritx.com (AKTX) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ENLV|Market Cap to Net Assets Ratio Q32 Bio Corp (QTTB)|GOVX (GeoVax Labs Inc) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Edesa Biotech Corp (EDSA)|Market Capitalization to Book Value Ratio iBio, Inc.|Carisma Therapeutics Inc - Market Value to Book Value|XTLB (XTL Biopharmaceuticals Ltd.) - Market Value to Book Value Ratio|BOLT: Market-to-Book Ratio|Market Value to Book Value Ratio HCWB|APVO (Aptevo Therapeutics Inc.) - Market-to-Book Ratio|AIM (AIM ImmunoTech Inc.) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio ADTX|GRI - Market Value to Book Value Ratio|Market Capitalization to Net Assets XORTX Therapeutics Inc (XRTX)|Market Capitalization to Book Value Ratio ReShape Lifesciences|Market Value to Book Value Revelation Biosciences Corp REVB|Indaptus Therapeutics - Market Capitalization to Book Value Ratio|SCNI: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio calcimedica.com CALI|AFMD (Affimed N.V.) - Market Value to Book Value|Market Value to Book Value Ratio ALLK|Market Cap to Net Assets Ratio IGM Bio|Market Capitalization to Book Value Ratio ITOS|Market Capitalization to Book Value Ratio oceanbiomedical.com OCEA|Market Cap to Net Assets Ratio TC BioPharm|Market Value to Book Value Third Harmonic Bio Inc. THRD